Role of Nitric oxide in the renal and systemic vasodilatory responses to platelet-activating factor in the rat, in vivo
- PMID: 12886044
- DOI: 10.1159/000071882
Role of Nitric oxide in the renal and systemic vasodilatory responses to platelet-activating factor in the rat, in vivo
Abstract
Background/aim: Chemical mediator(s) involved in the renal vasodilatory and systemic hypotensive effects of platelet-activating factor (PAF) remain unresolved. Because nitric oxide (NO) and PAF have many similar cardiovascular actions, we examined whether endogenous NO contributes to the renal and systemic actions of PAF.
Methods: PAF was administered into the renal arterial or systemic venous circulation of anesthetized rats. The change in renal blood flow (RBF) and/or mean arterial blood pressure (MAP) was recorded in the absence and presence of NO synthase inhibition.
Results: Transient exposure of the renal vacsular bed to intrarenal PAF boluses (1-10 ng kg(-1)) resulted in an immediate increase in RBF that was partially inhibited by the intrarenal administration of a NO synthase inhibitor, whereas the ensuing rapid fall in MAP was unaffected by NO synthase blockade. A sustained exposure to intrarenal PAF infusion (2.5 ng min(-1) kg(-1)) in intrarenal NO synthase inhibitor-treated rats (hypertensive with vasoconstricted kidneys) had no effect on RBF and MAP, which was in contrast to the increase in RBF and modest fall in MAP in control intrarenal vasopressin-treated rats (hypertensive with vasoconstricted kidneys). To dissociate the influence of systemic hypotension on the RBF response, rat kidneys were denervated and MAP elevated by a pressor agent whilst maintaining renal arterial blood pressure constant. Subsequent intrarenal PAF infusion at 2.5 and 10 ng min(-1) kg(-1) resulted in a substantial rise in RBF and modest fall in MAP, responses that were abolished by intrarenal NO synthase inhibition at the lower intrarenal PAF infusion or abolished/attenuated at the higher intrarenal PAF infusion. Additional experiments administered drugs intravenously to exclude the possibility that the modified MAP response by NO synthase inhibition was related to the drugs being administered into the kidney. Intravenous PAF boluses (0.1-1 microg kg(-1)) resulted in a transient fall in MAP that was independent of the NO pathway, whereas the systemic hypotension induced by intravenous PAF infusion (10 ng min(-1) kg(-1)) was greatly attenuated by NO synthase inhibition.
Conclusion: NO has a major role in mediating the renal and peripheral vasodilatory responses induced by a sustained exposure to PAF in the rat, whereas NO's overall contribution was less or absent during transient PAF exposure.
Similar articles
-
Platelet-activating factor and solute transport processes in the kidney.Am J Physiol Renal Physiol. 2003 Feb;284(2):F274-81. doi: 10.1152/ajprenal.00117.2002. Am J Physiol Renal Physiol. 2003. PMID: 12529272
-
Intrarenal haemodynamics and renal dysfunction in endotoxaemia: effects of nitric oxide synthase inhibition.Br J Pharmacol. 1997 Aug;121(8):1824-30. doi: 10.1038/sj.bjp.0701335. Br J Pharmacol. 1997. PMID: 9283724 Free PMC article.
-
Selective inhibition of vasoconstrictor responses by platelet-activating factor in rat kidney.Am J Physiol. 1991 Jul;261(1 Pt 2):F108-16. doi: 10.1152/ajprenal.1991.261.1.F108. Am J Physiol. 1991. PMID: 1907104
-
Recent findings on the mode of action of laxatives: the role of platelet activating factor and nitric oxide.Trends Pharmacol Sci. 1998 Oct;19(10):403-5. doi: 10.1016/s0165-6147(98)01249-8. Trends Pharmacol Sci. 1998. PMID: 9803830 Review.
-
Role of the endothelium-dependent relaxing factor nitric oxide on renal function.J Am Soc Nephrol. 1992 Mar;2(9):1371-87. doi: 10.1681/ASN.V291371. J Am Soc Nephrol. 1992. PMID: 1627761 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous